Do VC groups love the Web more than biotech?

CNET's Jim Kerstetter takes a look at biotech's anemic performance in the latest round of M&A deals and concludes that the investment crowd just loves the Internet more. There were 41 M&A deals in the first quarter for IT companies compared to just five in the life sciences. The reason? Kerstetter is betting that investors just feel a lot more comfortable now when they can look to an Internet play to pay off in two or three years. That kind of return is just about unheard of in the biotech space, where years of labor and high risk are a common feature of the industry. Of course, the life sciences industry as a whole attracted $9.1 billion in 862 deals last year, according to Thomson Financial and the NVCA. That's almost a third of all venture investing last year and a big increase over 2006's $7.6 billion. But that's long-term investment money, says Kerstetter. And VCs see the Web as the safer call these days.  

- check out the opinions at CNET

Related Articles:
Rocky market puts freeze on biotech deal-making. Report
Dealmaking stays big even as the markets tremble. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Deal-making hits a faster pace in '07. Report
Top 20 VC deals of 2007. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.